The role of prognostic stratification on prescription of anticoagulants in older patients with atrial fibrillation: a multicenter, observational, prospective European study (EUROSAF).


Journal

Annals of medicine
ISSN: 1365-2060
Titre abrégé: Ann Med
Pays: England
ID NLM: 8906388

Informations de publication

Date de publication:
12 2022
Historique:
entrez: 5 9 2022
pubmed: 6 9 2022
medline: 9 9 2022
Statut: ppublish

Résumé

Literature suggests that different risks of mortality could influence physicians in prescribing or not anticoagulants in older patients with atrial fibrillation (AF). The Multidimensional Prognostic Index (MPI) can be considered a tool for the detection of multidimensional frailty. The aim of this cross-sectional study was to evaluate whether prescription patterns of oral anticoagulants exist, based on MPI values. Older hospitalised patients (age ≥ 65 years) with non-valvular AF were included across 24 European centres. MPI was calculated using validated and standardised tools derived from a comprehensive geriatric assessment. Other functional and clinical information were collected to calculate indexes specific for haemorrhagic and thromboembolic risk in AF. Altogether, 2,012 participants affected by AF (mean age was 83.2 ± 7.5, range: 65-104 years), with a higher presence of women (57.0%), were included. Overall, 440 took vitamin K antagonists VKAs (22.0%), 667 (33.4%) direct oral anticoagulants (DOACs), whilst 44.6% did not take any anticoagulant treatment. Prescription of anticoagulants was associated with MPI values, with people taking anticoagulants having lower mean MPI values. Anticoagulant therapy was not used in 53.1% of the group with the highest risk of mortality, compared with 32.3% of those in the group with the lowest mortality risk. People with higher scores in MPI were less frequently treated with anticoagulant therapy, after adjusting for several potential confounders. The EURopean study of Older Subjects with Atrial Fibrillation (EUROSAF) suggested that almost half of the older persons with AF do not receive anticoagulants and that MPI is an important determinant in prescribing or not anticoagulants.

Sections du résumé

BACKGROUND
Literature suggests that different risks of mortality could influence physicians in prescribing or not anticoagulants in older patients with atrial fibrillation (AF). The Multidimensional Prognostic Index (MPI) can be considered a tool for the detection of multidimensional frailty. The aim of this cross-sectional study was to evaluate whether prescription patterns of oral anticoagulants exist, based on MPI values.
METHODS
Older hospitalised patients (age ≥ 65 years) with non-valvular AF were included across 24 European centres. MPI was calculated using validated and standardised tools derived from a comprehensive geriatric assessment. Other functional and clinical information were collected to calculate indexes specific for haemorrhagic and thromboembolic risk in AF.
RESULTS
Altogether, 2,012 participants affected by AF (mean age was 83.2 ± 7.5, range: 65-104 years), with a higher presence of women (57.0%), were included. Overall, 440 took vitamin K antagonists VKAs (22.0%), 667 (33.4%) direct oral anticoagulants (DOACs), whilst 44.6% did not take any anticoagulant treatment. Prescription of anticoagulants was associated with MPI values, with people taking anticoagulants having lower mean MPI values. Anticoagulant therapy was not used in 53.1% of the group with the highest risk of mortality, compared with 32.3% of those in the group with the lowest mortality risk. People with higher scores in MPI were less frequently treated with anticoagulant therapy, after adjusting for several potential confounders.
CONCLUSIONS
The EURopean study of Older Subjects with Atrial Fibrillation (EUROSAF) suggested that almost half of the older persons with AF do not receive anticoagulants and that MPI is an important determinant in prescribing or not anticoagulants.

Identifiants

pubmed: 36062815
doi: 10.1080/07853890.2022.2117407
pmc: PMC9448408
doi:

Substances chimiques

Anticoagulants 0

Banques de données

ClinicalTrials.gov
['NCT02973984']

Types de publication

Journal Article Multicenter Study Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2411-2419

Références

Clin Epidemiol. 2014 Jun 16;6:213-20
pubmed: 24966695
J Gerontol A Biol Sci Med Sci. 2019 Sep 15;74(10):1643-1649
pubmed: 30329033
Ther Adv Drug Saf. 2011 Apr;2(2):45-58
pubmed: 25083201
Int J Environ Res Public Health. 2021 Nov 26;18(23):
pubmed: 34886161
Drugs Aging. 2013 Dec;30(12):949-58
pubmed: 24170233
J Gerontol A Biol Sci Med Sci. 2021 Aug 13;76(9):1678-1685
pubmed: 32941606
Aging Clin Exp Res. 2020 May;32(5):861-868
pubmed: 32180170
Urol Nurs. 2007 Feb;27(1):93-4
pubmed: 17390935
Stroke. 2006 Apr;37(4):1075-80
pubmed: 16527999
Eur Geriatr Med. 2018 Apr;9(2):149-154
pubmed: 34654263
Open Heart. 2021 Aug;8(2):
pubmed: 34344724
Ageing Res Rev. 2020 Jul;60:101047
pubmed: 32171786
Lancet. 2019 Oct 12;394(10206):1376-1386
pubmed: 31609229
J Am Geriatr Soc. 1975 Oct;23(10):433-41
pubmed: 1159263
JAMA. 2012 Jan 11;307(2):199-200
pubmed: 22235093
Europace. 2021 Oct 9;23(10):1528-1538
pubmed: 34279604
J Am Geriatr Soc. 2016 Jul;64(7):1416-24
pubmed: 27295351
Gerontologist. 1969 Autumn;9(3):179-86
pubmed: 5349366
Rejuvenation Res. 2008 Feb;11(1):151-61
pubmed: 18173367
Mon Bull Minist Health Public Health Lab Serv. 1966 Nov;25:238-68
pubmed: 6013600
BMC Med Res Methodol. 2012 Jun 20;12:82
pubmed: 22716998
JAMA Intern Med. 2021 Aug 1;181(8):1121-1123
pubmed: 33970197
Intern Med. 2021;60(4):495-506
pubmed: 33583930
Age Ageing. 2021 May 5;50(3):772-779
pubmed: 33951158
J Am Geriatr Soc. 2020 Jan;68(1):147-154
pubmed: 31574165
J Am Med Dir Assoc. 2015 May 1;16(5):358-64
pubmed: 25680239
Ageing Res Rev. 2021 Dec;72:101498
pubmed: 34700009
J Clin Med. 2019 Apr 24;8(4):
pubmed: 31022899
Eur Heart J. 2021 Feb 1;42(5):373-498
pubmed: 32860505
J Nutr Health Aging. 2009 Nov;13(9):782-8
pubmed: 19812868
J Nutr Health Aging. 2016 Feb;20(2):218-30
pubmed: 26812520
J Gen Intern Med. 2022 Mar;37(4):730-736
pubmed: 33948795
J Am Geriatr Soc. 2008 Oct;56(10):1926-31
pubmed: 18811613
J Am Geriatr Soc. 2017 Feb;65(2):241-248
pubmed: 28039855

Auteurs

Alberto Pilotto (A)

Geriatrics Unit, Department of Geriatric Care, OrthoGeriatrics and Rehabilitation, E.O. Galliera Hospital, Genova, Italy.
Department of Interdisciplinary Medicine, University of Bari "Aldo Moro", Bari, Italy.

Nicola Veronese (N)

Geriatrics Unit, Department of Internal Medicine, University of Palermo, Palermo, Italy.

Maria Cristina Polidori (MC)

Ageing Clinical Research, Department II of Internal Medicine and Center for Molecular Medicine Cologne, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.

Timo Strandberg (T)

University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

Eva Topinkova (E)

First Faculty of Medicine, Charles University in Prague, Czech Republic.

Alfonso J Cruz-Jentoft (AJ)

Servicio de Geriatría, Hospital Universitario Ramón y Cajal (IRYCIS), Madrid, Spain.

Carlo Custodero (C)

Department of Interdisciplinary Medicine, University of Bari "Aldo Moro", Bari, Italy.

Stefania Maggi (S)

National Research Council, Neuroscience Section, Padova, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH